InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
